vimarsana.com

Latest Breaking News On - Immunos therapeutics - Page 1 : vimarsana.com

ImmunOs Therapeutics Presents Details of Novel Bispecific Anti-Tumor Molecules at ESMO Immuno-Oncology Congress 2023

ImmunOs Therapeutics Presents Overview of Phase 1a/b Trial of Lead Compound IOS-1002

Evaluation of IOS-1002, a LILRB1 (ILT2), LILRB2 (ILT4), KIR3DL1 targeting agent, as monotherapy and in combination with pembrolizumab in advanced solid tumorsTrial overview presented at ESMO Congress 2023 (Madrid, Spain)Dose

ImmunOs Therapeutics Announces Clinical Trial Collaboration with Merck & Co , Inc , Rahway,

- Evaluation of IOS-1002, a LILRB1 (ILT2), LILRB2 (ILT4), KIR3DL1 targeting agent, in combination with KEYTRUDA® (pembrolizumab) as part of ongoing Phase 1a/b trial in advanced solid tumors

ImmunOs Therapeutics Announces Appointment of Joseph Leveque, MD, to its Board of Directors

ImmunOs Therapeutics Announces Appointment of Joseph Leveque, MD, to its Board of Directors
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.